Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Ligand Pharmaceuticals, Inc shares valued at $1,350,012 were sold by Gray Nancy Ryan on Nov 07 ’25. At $205.45 per share, Gray Nancy Ryan sold 6,571 shares. The insider’s holdings dropped to 8,094 shares worth approximately $1.67 million following the completion of this transaction.
Also, LAMATTINA JOHN L sold 4,179 shares, netting a total of over 858,576 in proceeds. Following the sale of shares at $205.45 each, the insider now holds 30,724 shares.
Before that, NANCY GRAY had added 6,571 shares to its account. In a trade valued at $1,350,012, the Director bought Ligand Pharmaceuticals, Inc shares for $205.45 each.
As published in their initiating research note from Stifel on April 10, 2025, Ligand Pharmaceuticals, Inc [LGND] has been a Buy and the price target has been revised to $143. Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in early October. As of July 30, 2024, RBC Capital Mkts has initiated its “an Outperform” rating for LGND.
Analyzing LGND Stock Performance
On last trading session, Ligand Pharmaceuticals, Inc [NASDAQ: LGND] rose 1.30% to $206.16. The stock’s lowest price that day was $203.23, but it reached a high of $207.24 in the same session. During the last five days, there has been a surge of approximately 0.05%. Over the course of the year, Ligand Pharmaceuticals, Inc shares have jumped approximately 72.97%. Shares of the company reached a 52-week high of $212.49 on 11/11/25 and a 52-week low of $93.58 on 04/09/25.
Support And Resistance Levels for Ligand Pharmaceuticals, Inc (LGND)
According to the 24-hour chart, there is a support level at 203.85, which, if violated, would cause prices to drop to 201.53. In the upper region, resistance lies at 207.86. The next price resistance is at 209.55. RSI (Relative Strength Index) is 60.18 on the 14-day chart, showing neutral technical sentiment.
Is Ligand Pharmaceuticals, Inc subject to short interest?
Stocks of Ligand Pharmaceuticals, Inc saw a sharp steep in short interest on 2025-11-14 dropping by -0.13 million shares to 1.05 million. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 1.18 million shares. A decline of -12.44% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.55 of the overall float, the days-to-cover ratio (short ratio) decline to 5.55.
Which companies own the most shares of Ligand Pharmaceuticals, Inc (LGND)?
In terms of Ligand Pharmaceuticals, Inc share price expectations, FactSet research, analysts set an average price target of 231 in the next 12 months, up nearly 13.5% from the previous closing price of $203.52. Analysts anticipate Ligand Pharmaceuticals, Inc stock to reach 250 by 2025, with the lowest price target being 220. In spite of this, 5 analysts ranked Ligand Pharmaceuticals, Inc stock as Buy at the end of 2025. On February 04, 2021, H.C. Wainwright assigned a price target of “a Buy” to the stock and reiterated coverage with a $310.
